 BOSTON, MA ACCESSWIRE May 18, 2022 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 9:30 AM EDT. 